Q2 profit pressured, H2 recovery and new crop contract guided

Management guided margin improvementOrder pipeline disclosedMulti-year targets disclosedInvestor Communications View source PDF Explain this filing

HIKAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.7%Reaction day

₹220.62

prior close

₹219.40

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 173sector-0.2%-0.5% vs sector

On the reaction day the stock moved 0.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-1.3

15m

-1.4

30m

-1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.7pendingpending-0.2-0.5

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 revenue was INR434 crore, EBITDA INR45 crore at a 10.3% margin, and net loss INR6 crore. H1 revenue was INR837 crore with a 9.8% EBITDA margin. Higher input costs pressured crop protection. Management reiterated mid-teen FY27 revenue growth and substantial profit improvement, expecting H2 to outperform H1. A multiyear European crop contract should launch by FY27 end; Animal Health aims for INR400 crore revenue by FY30.

Likely market impact

Medium term: the crop contract and FY30 Animal Health target aid growth, but input costs, pricing pressure and US FDA timing may cap near-term margins.